Instagram Ern-EyeFacebook Ern-EyeTwitter Ern-EyeLinkedIn Ern-EyeYouTube Ern-EyeHow to use the speech recognition tool?
NCT03326336
PIONEER
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects
With Retinitis Pigmentosa (PIONEER).
Type: Interventional
Status of the trial: Recruiting
Orphan Drug Recognition: No
Inclusion
- Opening Date: 2018-01-23
- Closing Date: 2024-05-01
Criteria
Children: No
Adults: Yes
Funder Type: industry
HCP: Principal investigators
HCP: Other investigators
Within ERN-EYE members
Workgroups
Retinal Rare Eye Diseases (WG1)
This ERN is supported by:
